Climb Bio Net Worth
Climb Bio Net Worth Breakdown | CLYM |
Climb Bio Net Worth Analysis
Climb Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Climb Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Climb Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Climb Bio's net worth analysis. One common approach is to calculate Climb Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Climb Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Climb Bio's net worth. This approach calculates the present value of Climb Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Climb Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Climb Bio's net worth. This involves comparing Climb Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Climb Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Climb Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Climb Bio's net worth research are outlined below:
| Climb Bio is way too risky over 90 days horizon | |
| Climb Bio appears to be risky and price may revert if volatility continues | |
| Climb Bio was previously known as ELYM Old and was traded on NASDAQ Exchange under the symbol ELYM. | |
| Net Loss for the year was (73.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Climb Bio generates negative cash flow from operations | |
| Climb Bio has a frail financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Is Climb Bio Inc. stock poised for growth - Gold Moves AI Driven Stock Movement Reports - Newser |
Climb Bio Target Price Consensus
Climb target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Climb Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Climb analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Climb stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Climb Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationClimb Bio Target Price Projection
Climb Bio's current and average target prices are 2.39 and 9.00, respectively. The current price of Climb Bio is the price at which Climb Bio is currently trading. On the other hand, Climb Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Climb Bio Market Quote on 10th of September 2025
Target Price
Analyst Consensus On Climb Bio Target Price
Follow Climb Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 167.38 M.Market Cap |
|
Project Climb Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.35) | (0.37) |
When accessing Climb Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Climb Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Climb Bio's profitability and make more informed investment decisions.
Evaluate Climb Bio's management efficiency
Climb Bio has return on total asset (ROA) of (0.1583) % which means that it has lost $0.1583 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2292) %, meaning that it created substantial loss on money invested by shareholders. Climb Bio's management efficiency ratios could be used to measure how well Climb Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 10th of September 2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.41. At this time, Climb Bio's Non Current Assets Total are very stable compared to the past year. As of the 10th of September 2025, Non Currrent Assets Other is likely to grow to about 423.1 K, while Other Current Assets are likely to drop about 2.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.40 | 4.07 | |
| Tangible Book Value Per Share | 4.40 | 4.07 | |
| Price Book Value Ratio | 0.41 | 0.39 | |
| Price Fair Value | 0.41 | 0.39 | |
| Enterprise Value | -3.1 K | -2.9 K |
The strategic vision of Climb Bio management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Climb Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Climb Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Climb Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Climb Bio time-series forecasting models is one of many Climb Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Climb Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Climb Bio Earnings per Share Projection vs Actual
Climb Bio Corporate Management
| Chandra JD | VP Counsel | Profile | |
| Jo PalmerPhillips | Chief Officer | Profile | |
| Emily CPA | Senior Officer | Profile | |
| Cindy MBA | Senior Finance | Profile | |
| Emily Pimblett | Chief Officer | Profile | |
| Nishi MD | Senior Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.